Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01650584 · ClinicalTrials.gov registry record · NA
Evaluation of Ocular Comfort With ISTA Tears vs Systane
A NA study of Dry Eye Disease, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT01650584 is a NA study of Dry Eye Disease that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 35 participants, below the 254-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01650584, a NA study of Dry Eye Disease, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the comfort preference of ISTA Tears vs Systane in patients with dry eye disease (DED)
Conditions Studied
Interventions
- DRUG ISTA Tears
- DRUG Systane
Study Locations (1)
California
- ISTA Pharmaceuticals, Inc. - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01650584
The ClinicalTrials.gov registry entry for NCT01650584 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 254-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (86% lower). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which ISTA Tears is the first listed.
NCT01650584 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01650584 about?
NCT01650584 is a clinical study titled "Evaluation of Ocular Comfort With ISTA Tears vs Systane". To assess the comfort preference of ISTA Tears vs Systane in patients with dry eye disease (DED)
What is the current status of trial NCT01650584?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2012-06. Estimated completion is 2013-01.
What conditions does trial NCT01650584 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT01650584?
The interventions under investigation include: ISTA Tears (DRUG), Systane (DRUG).
Who is sponsoring clinical trial NCT01650584?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01650584 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
ACTIVE NOT RECRUITING · NA
-
The Visual Effect of an Investigational Artificial Tear in the Tear Layer.
COMPLETED · NA
-
In Vivo Confocal Microscopic Analysis of Corneal Nerve Changes After ProKera Slim® for Dry Eye
COMPLETED · NA
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
RECRUITING · Phase 4
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.